Abstract
Pancreatic cancer has high incidence and mortality rates, and effective treatment remains a clinical challenge. As deregulation of the cytokine transforming growth factor beta (TGF-β) contributes to the progression of pancreatic carcinoma, the TGF-β pathway has been targeted using various strategies, including small molecule inhibitors of TGF-βRI, TGF-β-specific neutralizing antibodies and antisense compounds. As increased TGF-β2 levels in serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis, inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009) is a promising approach.
Keywords: Pancreatic cancer, transforming growth factor beta, tumor microenvironment, immunosuppression, targeted therapies, trabedersen (AP 12009), small molecule inhibitors of TGF-βRI, tumor tissue, antisense compounds, pancreatic adenocarcinoma carries, epithelial cells, antitumoral immune response, growth factors, unique microenvironment harbors, chronic pancreatitis tissue
Current Pharmaceutical Biotechnology
Title: Transforming Growth Factor Beta in Pancreatic Cancer
Volume: 12 Issue: 12
Author(s): Andreas Hilbig and Helmut Oettle
Affiliation:
Keywords: Pancreatic cancer, transforming growth factor beta, tumor microenvironment, immunosuppression, targeted therapies, trabedersen (AP 12009), small molecule inhibitors of TGF-βRI, tumor tissue, antisense compounds, pancreatic adenocarcinoma carries, epithelial cells, antitumoral immune response, growth factors, unique microenvironment harbors, chronic pancreatitis tissue
Abstract: Pancreatic cancer has high incidence and mortality rates, and effective treatment remains a clinical challenge. As deregulation of the cytokine transforming growth factor beta (TGF-β) contributes to the progression of pancreatic carcinoma, the TGF-β pathway has been targeted using various strategies, including small molecule inhibitors of TGF-βRI, TGF-β-specific neutralizing antibodies and antisense compounds. As increased TGF-β2 levels in serum or tumor tissue of patients with pancreatic cancer correlated with poor prognosis, inhibition of TGF-β2 synthesis via the antisense oligonucleotide trabedersen (AP 12009) is a promising approach.
Export Options
About this article
Cite this article as:
Hilbig Andreas and Oettle Helmut, Transforming Growth Factor Beta in Pancreatic Cancer, Current Pharmaceutical Biotechnology 2011; 12 (12) . https://dx.doi.org/10.2174/138920111798808356
DOI https://dx.doi.org/10.2174/138920111798808356 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design <i>In vivo</i> Anticancer Potential of Hydroxamic Acid Derivatives
Current Topics in Medicinal Chemistry In Vitro High Throughput Phage Display Selection of Ovarian Cancer Avid Phage Clones for Near-Infrared Optical Imaging
Combinatorial Chemistry & High Throughput Screening Inhibitors of the TGF-β Superfamily and their Clinical Applications
Mini-Reviews in Medicinal Chemistry Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Meet Our Editorial Board Member
Protein & Peptide Letters Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Prediction of the Ebola Virus Infection Related Human Genes Using Protein-Protein Interaction Network
Combinatorial Chemistry & High Throughput Screening Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Potential Therapeutic Effects of Na+/Ca2+ Exchanger Inhibition in Cardiac Diseases
Current Medicinal Chemistry Drug Delivery Systems and Strategies to Overcome the Barriers of Brain
Current Pharmaceutical Design Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA